Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9279585 | 0.79 | KDM4E (0.44) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL15459823 | 0.79 | ALDH1A1 (0.67) | KDM4EALDH1A1SMN1; SMN2GAATP53 | |
| SCHEMBL22589672 | 0.78 | NPC1 (0.48) | KDM4EALDH1A1SMN1; SMN2GAATP53 | |
| SCHEMBL29615193 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1TP53TSHRNPC1 | |
| SCHEMBL4455251 | 0.78 | ALDH1A1 (0.92) | KDM4EALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL15260226 | 0.78 | KDM4E (0.66) | KDM4EALDH1A1TP53TSHRNPC1 | |
| SCHEMBL2024990 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1TP53TSHRNPC1 | |
| SCHEMBL31372502 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1TP53TSHRNPC1 | |
| SCHEMBL23425648 | 0.78 | MAOB (0.70) | KDM4EALDH1A1MAOA | |
| SCHEMBL3569146 | 0.78 | KDM4E (0.66) | KDM4EALDH1A1SMN1; SMN2GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344626-B2 | Pharmaceutical compounds and therapeutic methods | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-07-01 | — | — | US | disclosed |
| US-20220185827-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220185827-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-06-16 | — | — | US | disclosed |
| WO-2020219587-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344626-B2 | Pharmaceutical compounds and therapeutic methods | SLC30A5, SLC39A11, SLC30A7 | KDM4E 2909/4885ALDH1A1 2006/4885SMN1; SMN2 2994/4885 |
| US-20220185827-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | SLC30A5, SLC39A11, SLC30A7 | KDM4E 2909/4885ALDH1A1 2006/4885SMN1; SMN2 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.